UK contract research SME specializing in predictive toxicology: in vitro assays, organ-on-chip models, and computational AOP-based risk assessment.
Cyprotex is a contract research organization (CRO) specializing in predictive toxicology — they provide in vitro and computational services that help pharmaceutical and chemical companies assess the safety of compounds before expensive animal or clinical studies. Their core business is ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling, delivered through a combination of wet-lab assays and in silico modelling. In H2020 projects they contributed expertise in adverse outcome pathways (AOPs), biokinetic modelling, and advanced 3D cell culture systems including organoids and organ-on-chip platforms. They operate as a specialized service provider within large European research consortia, supplying validated toxicological data and computational tools to academic and regulatory partners.
In EU-ToxRisk (2016–2021) Cyprotex contributed cheminformatics, biokinetics modelling, and adverse outcome pathway (AOP) development for mechanism-based risk assessment of repeated-dose and reproductive toxicity.
In SCREENED (2019–2024) Cyprotex worked with organoids, decellularized extracellular matrix, bioprinting, and organ-on-chip platforms to build a multistage thyroid model for endocrine disruptor screening.
SCREENED focused specifically on detecting thyroid-active endocrine-disrupting chemicals using biologically relevant test systems, an area Cyprotex entered after 2019.
Both EU-ToxRisk and SCREENED are explicitly oriented toward replacing or reducing animal testing by generating mechanism-based data acceptable to EU and ECHA risk assessment frameworks.
In their first H2020 project (EU-ToxRisk, starting 2016), Cyprotex focused on the computational and systems biology side of toxicology — building AOPs, running biokinetic simulations, and applying cheminformatics to model how chemicals cause harm at the molecular level. By 2019, with SCREENED, the emphasis shifted toward physically constructing sophisticated 3D tissue models: organoids, bioprinted scaffolds, and organ-on-chip devices that mimic real organ behaviour in the lab. This is a meaningful transition from modelling toxicity in silico to demonstrating it in increasingly organ-realistic in vitro systems — a trajectory the whole field is moving along as regulators push for more human-relevant test data.
Cyprotex is moving toward complex microphysiological systems (organoids, organ-on-chip), suggesting future collaborations would suit consortia developing next-generation human-relevant test platforms for regulatory toxicology or pharmaceutical safety screening.
Cyprotex participates exclusively as a consortium member — never a coordinator across their H2020 record — which is consistent with their role as a specialist service provider that plugs into larger research programs. They joined consortia of significant scale: EU-ToxRisk in particular was a flagship program with dozens of partners, meaning Cyprotex is comfortable operating within complex, multi-stakeholder research structures. Their 49 unique partners across 14 countries suggests broad exposure but no evidence of a tight repeated-partner network, pointing to a project-by-project engagement model.
Cyprotex has collaborated with 49 unique partners across 14 countries through just two projects, indicating they were embedded in large, geographically diverse consortia rather than small bilateral partnerships. No strong geographic concentration is visible from the available data.
Cyprotex sits at the intersection of commercial CRO service delivery and academic-grade research innovation, which is rare — most participants in toxicology consortia are universities or regulatory institutes, not commercial labs with validated GLP-adjacent workflows. This means they can bridge the gap between research-stage methods and industry-ready assay packages, making them valuable to both pharma companies seeking validated safety tools and consortia that need a partner capable of translating experimental protocols into deployable services. Their dual capability in computational modelling (cheminformatics, AOPs) and wet-lab 3D models (organoids, organ-on-chip) also makes them unusually self-contained for a small SME.
